Urine Osmolarity Predicts the Body Weight-Reduction Response to Tolvaptan in Chronic Kidney Disease Patients: A Retrospective, Observational Study

Nephron

Volumn 130, Issue 1, 2015, Pages 8-12

  Iwatani, Hirotsugu ^a   Kawabata, Hiroaki ^a   Sakaguchi, Yusuke ^a   Yamamoto, Ryohei ^a   Hamano, Takayuki ^a   Rakugi, Hiromi ^a   Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Tolvaptan; Urine osmolarity

Indexed keywords

CREATININE; DIURETIC AGENT; SODIUM; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT LOSS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; FLUID INTAKE; HEART FAILURE; HUMAN; LIVER CIRRHOSIS; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TREATMENT RESPONSE; URINE OSMOLALITY; URINE VOLUME; COMPLICATION; DRUG EFFECTS; KIDNEY FUNCTION TEST; MIDDLE AGED; OSMOLARITY; RECEIVER OPERATING CHARACTERISTIC; RENAL INSUFFICIENCY, CHRONIC; URINE; URODYNAMICS; WEIGHT REDUCTION;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; DIURETICS; FEMALE; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; ROC CURVE; URODYNAMICS; WEIGHT LOSS;

EID: 84965099207     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000381859     Document Type: Article

References (12)

1. Yamamura Y, Nakamura S, Itoh S, et al: OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-867.
2. Hirano T, Yamamura Y, Nakamura S, et al: Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292: 288-294.
3. Blair JE, Pang PS, Schrier RW, et al: Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011; 32: 2563-2572.
4. Gheorghiade M, Niazi I, Ouyang J, et al: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696.
5. Gheorghiade M, Gattis WA, O'Connor CM, et al: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971.
6. Gheorghiade M, Orlandi C, Burnett JC, et al: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005; 11: 260-269.
7. Imamura T, Kinugawa K, Shiga T, et al: Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients-association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
8. Imamura T, Kinugawa K, Fujino T, et al: Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-2249.
9. Otsuka T, Sakai Y, Ohno D, et al: The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol 2013; 17: 834-838.
10. Mori T, Oba I, Koizumi K, et al: Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial 2013; 29: 33-37.
11. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al: Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290:F273-F278.
12. Matsue Y, Suzuki M, Seya M, et al: Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 61: 169-174.